FDA Drug Label
MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information
Eli, 2022
GLP-1 & MetabolicFDA ApprovedS
Tirzepatide
Mounjaro / Zepbound
Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's FDA-approved dual GLP-1/GIP receptor agonist and the first approved twincretin therapy. SURMOUNT-1 trial demonstrated up to 22.5% average body weight reduction at 72 weeks with 15mg — the highest efficacy among approved obesity medications at time of approval. Also approved for obstructive sleep apnea reduction (2024).
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 10
- Research grade
- S
- Experience
- 23
- Activity
- 64
Overall check-ins
Trackers & reports
Overview
About Tirzepatide
Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's FDA-approved dual GLP-1/GIP receptor agonist and the first approved twincretin therapy. SURMOUNT-1 trial demonstrated up to 22.5% average body weight reduction at 72 weeks with 15mg — the highest efficacy among approved obesity medications at time of approval. Also approved for obstructive sleep apnea reduction (2024).
- Category
- GLP-1 & Metabolic
- Regulatory status
- FDA Approved
- Also known as
- Mounjaro / Zepbound
- Self-reports
- 7
Community
What 7 users report
7 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 14% · Mixed 0% · Unfavorable overall 86%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
7
Sleep
1
Mood
1
Energy
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Injection site irritation
3
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.4 to ≥ 5 mg (open-ended top bucket)
0.4–0.6 mg
1
5+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Research
Cited research (8)
Source
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff et al., 2022
ClinicalTrials.gov
Tirzepatide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías et al., 2021
PubMed
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
Frias et al., 2024
FDA Drug Label
ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information
Eli, 2023
PubMed
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey et al., 2023
PubMed
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff et al., 2025
Tools
Explore more
Explore
More ways to learn about Tirzepatide from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Tirzepatide?
This page summarizes 7 anonymized self-reports from PeptIQ users who track Tirzepatide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Tirzepatide?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Tirzepatide?
8 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Tirzepatide safe to use?
This wiki does not assess safety or recommend use. Tirzepatide is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Tirzepatide?
This wiki summarizes observational community reports and linked citations for Tirzepatide. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Tirzepatide for study-level context — not medical advice.
What is the legal status of Tirzepatide?
Tirzepatide is listed in PeptIQ as FDA Approved. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Tirzepatide?
Safety data quality for Tirzepatide varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Tirzepatide?
This page links 8 indexed sources for Tirzepatide. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.